Mutations in CIC and IDH1 cooperatively regulate 2-hydroxyglutarate levels and cell clonogenicity

Oncotarget

Volumn 5, Issue 17, 2014, Pages 7960-7979

  Chittaranjan, Suganthi ^a   Chan, Susanna ^a   Yang, Cindy ^a   Yang, Kevin C ^a   Chen, Vincent ^a   Moradian, Annie ^a,b   Firme, Marlo ^a   Song, Jungeun ^a   Go, Nancy E ^a,c   Blough, Michael D ^d   Chan, Jennifer A ^d   Gregory Cairncross, J ^d   Gorski, Sharon M ^a,c   Morin, Gregg B ^a,f   Yip, Stephen ^e   Marra, Marco A ^a,f  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

^c SIMON FRASER UNIVERSITY   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e VANCOUVER GENERAL HOSPITAL   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

2HG; ACLY; CIC; Citrate; IDH1; Oligodendroglioma

Indexed keywords

2 HYDROXYGLUTARIC ACID; ADENOSINE TRIPHOSPHATE CITRATE LYASE; CAPICUA TRANSCRIPTIONAL REPRESSOR PROTEIN; ISOCITRATE DEHYDROGENASE 1; REPRESSOR PROTEIN; UNCLASSIFIED DRUG; ALPHA-HYDROXYGLUTARATE; CIC PROTEIN, HUMAN; GLUTARIC ACID DERIVATIVE; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE;

ARTICLE; CANCER CELL LINE; CELL CLONING; CELL COMPARTMENTALIZATION; CELL NUCLEUS; CELL PROLIFERATION; CIC GENE; CONTROLLED STUDY; CYTOPLASM; FEMALE; GENE; GENE DELETION; GENE EXPRESSION; GENE MUTATION; HEK293 CELL LINE; HOG CELL LINE; HUMAN; HUMAN CELL; IDH1 GENE; IN VITRO STUDY; MITOCHONDRION; MUTANT; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; WILD TYPE; BRAIN TUMOR; GENETICS; IMMUNOPRECIPITATION; MASS SPECTROMETRY; METABOLISM; MUTATION; OLIGODENDROGLIOMA; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL LINE, TUMOR; GLUTARATES; HUMANS; IMMUNOPRECIPITATION; ISOCITRATE DEHYDROGENASE; MASS SPECTROMETRY; MUTATION; OLIGODENDROGLIOMA; REPRESSOR PROTEINS;

EID: 84907482179     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2401     Document Type: Article

References (58)

1. Bralten LB, Nouwens S, Kockx C, Erdem L, Hoogenraad CC, Kros JM, Moorhouse MJ, Sillevis Smitt PA, van der Spek P, van Ijcken W, Stubbs A, French PJ. Absence of Common Somatic Alterations in Genes on 1p and 19q in Oligodendrogliomas. PLoS ONE 2011; 6(7):e22000.
2. Yip S, Butterfield YS, Morozova O, Chittaranjan S, Blough MD, An J, Birol I, Chesnelong C, Chiu R, Chuah E, Corbett R, Docking R, Firme M, Hirst M, Jackman S, Karsan A et al. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J. Pathol. 2012; 226(1):7-16.
3. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl. Cancer Inst. 1998; 90(19):1473-1479.
4. Ino Y, Betensky RA, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, Ramsay DA, Cairncross JG, Louis DN. Molecular Subtypes of Anaplastic Oligodendroglioma Implications for Patient Management at Diagnosis. Clin. Cancer Res. 2001; 7(4):839-845.
5. Bettegowda C, Agrawal N, Jiao Y, Sausen M, Wood LD, Hruban RH, Rodriguez FJ, Cahill DP, McLendon R, Riggins G, Velculescu VE, Oba-Shinjo SM, Marie SKN, Vogelstein B, Bigner D, Yan H et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 2011; 333(6048):1453-1455.
6. Eisenreich S, Abou-El-Ardat K, Szafranski K, Campos Valenzuela JA, Rump A, Nigro JM, Bjerkvig R, Gerlach E-M, Hackmann K, Schröck E, Krex D, Kaderali L, Schackert G, Platzer M, Klink B. Novel CIC Point Mutations and an Exon-Spanning, Homozygous Deletion Identified in Oligodendroglial Tumors by a Comprehensive Genomic Approach Including Transcriptome Sequencing. PLoS ONE 2013; 8(9):e76623.
7. Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF, Rodriguez FJ, Rosemberg S, Oba-Shinjo SM, Nagahashi Marie SK, Bettegowda C, Agrawal N, Lipp E, Pirozzi C, Lopez G, He Y et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 2012; 3(7):709-722.
8. Sahm F, Koelsche C, Meyer J, Pusch S, Lindenberg K, Mueller W, Herold-Mende C, von Deimling A, Hartmann C. CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas. Acta Neuropathol. (Berl.) 2012; 123(6):853-860.
9. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He T-C, He Y, Hruban RH, Jallo GI, Mandahl N et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc. Natl. Acad. Sci. U. S. A. 2013; 110(15):6021-6026.
10. Lam YC, Bowman AB, Jafar-Nejad P, Lim J, Richman R, Fryer JD, Hyun ED, Duvick LA, Orr HT, Botas J, Zoghbi HY. ATAXIN-1 interacts with the repressor Capicua in its native complex to cause SCA1 neuropathology. Cell 2006; 127(7):1335-1347.
11. Lee C-J, Chan W-I, Cheung M, Cheng Y-C, Appleby VJ, Orme AT, Scotting PJ. CIC, a member of a novel subfamily of the HMG-box superfamily, is transiently expressed in developing granule neurons. Brain Res. Mol. Brain Res. 2002; 106(1-2):151-156.
12. Jiménez G, Guichet A, Ephrussi A, Casanova J. Relief of gene repression by torso RTK signaling: role of capicua in Drosophila terminal and dorsoventral patterning. Genes Dev. 2000; 14(2):224-231.
13. Goff DJ, Nilson LA, Morisato D. Establishment of dorsal-ventral polarity of the Drosophila egg requires capicua action in ovarian follicle cells. Dev. Camb. Engl. 2001; 128(22):4553-4562.
14. Roch F, Jiménez G, Casanova J. EGFR signalling inhibits Capicua-dependent repression during specification of Drosophila wing veins. Dev. Camb. Engl. 2002; 129(4):993-1002.
15. Tseng A-SK, Tapon N, Kanda H, Cigizoglu S, Edelmann L, Pellock B, White K, Hariharan IK. Capicua regulates cell proliferation downstream of the receptor tyrosine kinase/ras signaling pathway. Curr. Biol. CB 2007; 17(8):728-733.
16. Yoshimoto M, Graham C, Chilton-MacNeill S, Lee E, Shago M, Squire J, Zielenska M, Somers GR. Detailed cytogenetic and array analysis of pediatric primitive sarcomas reveals a recurrent CIC-DUX4 fusion gene event. Cancer Genet. Cytogenet. 2009; 195(1):1-11.
17. Kawamura-Saito M, Yamazaki Y, Kaneko K, Kawaguchi N, Kanda H, Mukai H, Gotoh T, Motoi T, Fukayama M, Aburatani H, Takizawa T, Nakamura T. Fusion between CIC and DUX4 up-regulates PEA3 family genes in Ewing-like sarcomas with t(4;19)(q35;q13) translocation. Hum. Mol. Genet. 2006; 15(13):2125-2137.
18. Dissanayake K, Toth R, Blakey J, Olsson O, Campbell DG, Prescott AR, MacKintosh C. ERK/p90(RSK)/14-3-3 signalling has an impact on expression of PEA3 Ets transcription factors via the transcriptional repressor capicúa. Biochem. J. 2011; 433(3):515-525.
19. Kim E, Lu H-C, Zoghbi HY, Song J-J. Structural basis of protein complex formation and reconfiguration by polyglutamine disease protein Ataxin-1 and Capicua. Genes Dev. 2013; 27(6):590-595.
20. Beckner ME, Fellows-Mayle W, Zhang Z, Agostino NR, Kant JA, Day BW, Pollack IF. Identification of ATP citrate lyase as a positive regulator of glycolytic function in glioblastomas. Int. J. Cancer J. Int. Cancer 2010; 126(10):2282-2295.
21. Oudard S, Boitier E, Miccoli L, Rousset S, Dutrillaux B, Poupon MF. Gliomas are driven by glycolysis: putative roles of hexokinase, oxidative phosphorylation and mitochondrial ultrastructure. Anticancer Res. 1997; 17(3C):1903-1911.
22. Wise DR, Ward PS, Shay JES, Cross JR, Gruber JJ, Sachdeva UM, Platt JM, DeMatteo RG, Simon MC, Thompson CB. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability. Proc. Natl. Acad. Sci. 2011; 108(49):19611-19616.
23. Costello LC, Franklin RB. A review of the important central role of altered citrate metabolism during the process of stem cell differentiation. J. Regen. Med. Tissue Eng. 2013; 2(1):1.
24. Icard P, Poulain L, Lincet H. Understanding the central role of citrate in the metabolism of cancer cells. Biochim. Biophys. Acta 2012; 1825(1):111-116.
25. Wellen KE, Hatzivassiliou G, Sachdeva UM, Bui TV, Cross JR, Thompson CB. ATP-Citrate Lyase Links Cellular Metabolism to Histone Acetylation. Science 2009; 324(5930):1076-1080.
26. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liau LM, Rabinowitz JD et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009; 462(7274):739.
27. Ward PS, Cross JR, Lu C, Weigert O, Abel-Wahab O, Levine RL, Weinstock DM, Sharp KA, Thompson CB. Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production. Oncogene 2012; 31(19):2491-2498.
28. Losman J-A, Looper RE, Koivunen P, Lee S, Schneider RK, McMahon C, Cowley GS, Root DE, Ebert BL, Kaelin WG. (R)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible. Science 2013; 339(6127):1621-1625.
29. Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, Campos C, Fabius AWM, Lu C, Ward PS, Thompson CB, Kaufman A, Guryanova O, Levine R, Heguy A, Viale A et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012; 483(7390):479-483.
30. Kelly JJP, Blough MD, Stechishin ODM, Chan JAW, Beauchamp D, Perizzolo M, Demetrick DJ, Steele L, Auer RN, Hader WJ, Westgate M, Parney IF, Jenkins R, Cairncross JG, Weiss S. Oligodendroglioma cell lines containing t(1;19)(q10;p10). Neuro-Oncol. 2010; 12(7):745-755.
31. Lynn BD, Turley EA, Nagy JI. Subcellular distribution, calmodulin interaction, and mitochondrial association of the hyaluronan-binding protein RHAMM in rat brain. J. Neurosci. Res. 2001; 65(1):6-16.
32. Gilquin B, Taillebourg E, Cherradi N, Hubstenberger A, Gay O, Merle N, Assard N, Fauvarque M-O, Tomohiro S, Kuge O, Baudier J. The AAA+ ATPase ATAD3A controls mitochondrial dynamics at the interface of the inner and outer membranes. Mol. Cell. Biol. 2010; 30(8):1984-1996.
33. Shaw G, Morse S, Ararat M, Graham FL. Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells. FASEB J. 2002; 16(8):869-871.
34. Post GR, Dawson G. Characterization of a cell line derived from a human oligodendroglioma. Mol. Chem. Neuropathol. Spons. Int. Soc. Neurochem. World Fed. Neurol. Res. Groups Neurochem. Cerebrospinal Fluid 1992; 16(3):303-317.
35. Long PM, Tighe SW, Driscoll HE, Moffett JR, Namboodiri AMA, Viapiano MS, Lawler SE, Jaworski DM. Acetate Supplementation Induces Growth Arrest of NG2/PDGFRa-Positive Oligodendroglioma-Derived Tumor-Initiating Cells. PLoS ONE 2013; 8(11):e80714.
36. Reitman ZJ, Jin G, Karoly ED, Spasojevic I, Yang J, Kinzler KW, He Y, Bigner DD, Vogelstein B, Yan H. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc. Natl. Acad. Sci. 2011; 108(8):3270-3275.
37. Balss J, Pusch S, Beck A-C, Herold-Mende C, Krämer A, Thiede C, Buckel W, Langhans C-D, Okun JG, von Deimling A. Enzymatic assay for quantitative analysis of (D)-2-hydroxyglutarate. Acta Neuropathol. (Berl.) 2012; 124(6):883-891.
38. Hanai J, Doro N, Sasaki AT, Kobayashi S, Cantley LC, Seth P, Sukhatme VP. Inhibition of lung cancer growth: ATP citrate lyase knockdown and statin treatment leads to dual blockade of mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3K)/AKT pathways. J. Cell. Physiol. 2012; 227(4):1709-1720.
39. Potapova IA, El-Maghrabi MR, Doronin SV, Benjamin WB. Phosphorylation of recombinant human ATP:citrate lyase by cAMP-dependent protein kinase abolishes homotropic allosteric regulation of the enzyme by citrate and increases the enzyme activity. Allosteric activation of ATP:citrate lyase by phosphorylated sugars. Biochemistry (Mosc.) 2000; 39(5):1169-1179.
40. Zaidi N, Swinnen JV, Smans K. ATP-citrate lyase: a key player in cancer metabolism. Cancer Res. 2012; 72(15):3709-3714.
41. Sun T, Hayakawa K, Bateman KS, Fraser ME. Identification of the Citrate-binding Site of Human ATP-Citrate Lyase Using X-ray Crystallography. J. Biol. Chem. 2010; 285(35):27418-27428.
42. Migita T, Narita T, Nomura K, Miyagi E, Inazuka F, Matsuura M, Ushijima M, Mashima T, Seimiya H, Satoh Y, Okumura S, Nakagawa K, Ishikawa Y. ATP Citrate Lyase: Activation and Therapeutic Implications in Non-Small Cell Lung Cancer. Cancer Res. 2008; 68(20):8547-8554.
43. Chu KY, Lin Y, Hendel A, Kulpa JE, Brownsey RW, Johnson JD. ATP-Citrate Lyase Reduction Mediates Palmitate-induced Apoptosis in Pancreatic Beta Cells. J. Biol. Chem. 2010; 285(42):32606-32615.
44. Klink B, Miletic H, Stieber D, Huszthy PC, Valenzuela JAC, Balss J, Wang J, Schubert M, Sakariassen PØ, Sundstrøm T, Torsvik A, Aarhus M, Mahesparan R, von Deimling A, Kaderali L, Niclou SP et al. A Novel, Diffusely Infiltrative Xenograft Model of Human Anaplastic Oligodendroglioma with Mutations in FUBP1, CIC, and IDH1. PLoS ONE 2013; 8(3):e59773.
45. Luchman HA, Stechishin OD, Dang NH, Blough MD, Chesnelong C, Kelly JJ, Nguyen SA, Chan JA, Weljie AM, Cairncross JG, Weiss S. An in vivo patient-derived model of endogenous IDH1-mutant glioma. Neuro-Oncol. 2012; 14(2):184-191.
46. Turyn J, Schlichtholz B, Dettlaff-Pokora A, Presler M, Goyke E, Matuszewski M, Kmieć Z, Krajka K, Swierczynski J. Increased activity of glycerol 3-phosphate dehydrogenase and other lipogenic enzymes in human bladder cancer. Horm. Metab. Res. Horm. Stoffwechselforschung Horm. Métabolisme 2003; 35(10):565-569.
47. Varis A, Wolf M, Monni O, Vakkari M-L, Kokkola A, Moskaluk C, Frierson H Jr, Powell SM, Knuutila S, Kallioniemi A, El-Rifai W. Targets of gene amplification and overexpression at 17q in gastric cancer. Cancer Res. 2002; 62(9):2625-2629.
48. Yancy HF, Mason JA, Peters S, Thompson CE, Littleton GK, Jett M, Day AA. Metastatic progression and gene expression between breast cancer cell lines from African American and Caucasian women. J. Carcinog. 2007; 6:8.
49. Bauer DE, Hatzivassiliou G, Zhao F, Andreadis C, Thompson CB. ATP citrate lyase is an important component of cell growth and transformation. Oncogene 2005; 24(41):6314-6322.
50. Hatzivassiliou G, Zhao F, Bauer DE, Andreadis C, Shaw AN, Dhanak D, Hingorani SR, Tuveson DA, Thompson CB. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 2005; 8(4):311-321.
51. Gozé C, Bezzina C, Gozé E, Rigau V, Maudelonde T, Bauchet L, Duffau H. 1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth. J. Neurooncol. 2012; 108(1):69-75.
52. Preusser M, Hoeftberger R, Woehrer A, Gelpi E, Kouwenhoven M, Kros JM, Sanson M, Idbaih A, Brandes AA, Heinzl H, Gorlia T, Hainfellner JA, van den Bent M. Prognostic value of Ki67 index in anaplastic oligodendroglial tumours-a translational study of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Histopathology 2012; 60(6):885-894.
53. Jin G, Pirozzi CJ, Chen LH, Lopez GY, Duncan CG, Feng J, Spasojevic I, Bigner DD, He Y, Yan H. Mutant IDH1 is required for IDH1 mutated tumor cell growth. Oncotarget 2012; 3(8):774-782.
54. Bralten LBC, Kloosterhof NK, Balvers R, Sacchetti A, Lapre L, Lamfers M, Leenstra S, de Jonge H, Kros JM, Jansen EEW, Struys EA, Jakobs C, Salomons GS, Diks SH, Peppelenbosch M, Kremer A et al. IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo. Ann. Neurol. 2011; 69(3):455-463.
55. Li S, Chou AP, Chen W, Chen R, Deng Y, Phillips HS, Selfridge J, Zurayk M, Lou JJ, Everson RG, Wu K-C, Faull KF, Cloughesy T, Liau LM, Lai A. Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation. Neuro-Oncol. 2013; 15(1):57-68.
56. Van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJB, Wesseling P, Frenay M, Tijssen CC, Lacombe D, Idbaih A, van Marion R, Kros JM, Dinjens WNM, Gorlia T, Sanson M. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2010; 16(5):1597-1604.
57. Sasaki M, Knobbe CB, Itsumi M, Elia AJ, Harris IS, Chio II C, Cairns RA, McCracken S, Wakeham A, Haight J, Ten AY, Snow B, Ueda T, Inoue S, Yamamoto K, Ko M et al. D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. Genes Dev. 2012; 26(18):2038-2049.
58. Piaskowski S, Bienkowski M, Stoczynska-Fidelus E, Stawski R, Sieruta M, Szybka M, Papierz W, Wolanczyk M, Jaskolski DJ, Liberski PP, Rieske P. Glioma cells showing IDH1 mutation cannot be propagated in standard cell culture conditions. Br. J. Cancer 2011; 104(6):968-970.